Martin Dreyling, MD of University of Munich Hospital in Grosshadern explains the difference between copanlisib and other PI3K inhibitors, specifically Idelalisib He argues that copanlisib seems to be better tolerated in patients than Idelalisib. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
What is the Difference Between Copanlisib and Other PI3K Inhibitors
